Adcock takeover offer may push company value to $1.5bn

Adcock's board received non-binding proposals that could lead to an offer for the whole company or a controlling stake, the Johannesburg-based maker of Panado painkillers and Corenza cold medicine said on Thursday.

The stock rose 8.9% to R67.50 by the close in Johannesburg, its highest level since November 2010, valuing the company at R11.7-billion ($1.29-billion).

The wording suggests there may be "multiple bids for the company", JPMorgan analysts Alex Comer and Avinash Kalkapersad wrote in a note dated yesterday.

"Under this scenario, we believe the stock could be worth R75.80 a share based on historic transaction multiples and a bid premium."

That would value Adcock at about $1.46-billion, according to data compiled by Bloomberg. The shares were down 1.1% at R66.75 by the close in Johannesburg.


The approaches probably came from foreign companies as there are no obvious South African bidders other than Bidvest Group, which had an offer for a controlling stake in Adcock rejected in March, Mathew Menezes, an analyst at Avior Research, said by phone from Johannesburg.

The latest proposals aren't from Bidvest, Adcock said in Thursday's statement.

Remains interested
Bidvest still wants to acquire Adcock and must get the same information made available to other bidders, chief executive Brian Joffe said.

"Bidvest's current position is that it remains interested in Adcock," Joffe said in an emailed response to questions on Friday.

"There is no impediment to Bidvest now making an offer direct to Adcock shareholders."

Bidvest offered to buy 60% of Adcock for about R6.2-billion ($685-million) on March 22.

The offer was half in cash, at R65 a share, and half in stock at a ratio of one Bidvest share for every four Adcock shares.

The bid values Adcock at R65.19 a share at current prices, 2.3% below the stock's cost today. Bidvest said last month it would take the offer directly to shareholders in the absence of support from the board.

Bidvest "will make a formal offer to the shareholders rather than an informal" one and at a higher price compared to the initial proposal, Kate Turner Smith, a pharmaceutical equity analyst at Cape Town-based BPI Capital Africa, said in a phone interview.

Launch pad
?Adcock has had a marketing and distribution agreement with US-based pharmaceutical company Merck, to sell non-prescription medicines as well as treatments for high blood pressure since 2010.

Merck spokesperson Kelley Dougherty declined to comment.

"Adcock would also offer an acquirer a potential launch pad into the rest of Africa," JPMorgan's Comer and Kalkapersad said.

Weakness in the South African rand has also made "Adcock more attractive to potential international buyers", the JPMorgan analysts wrote.

The rand has declined 6.8% against the dollar this year, the worst performer of 24 emerging market currencies tracked by Bloomberg.

Adcock shares have gained 6% in the past 12 months, compared with a 72% increase at larger competitor Aspen Pharmacare Holdings, 18.2% owned by Brentford, England-based GlaxoSmithKline.

Adcock has fallen behind Aspen because of "product losses, a previously weak tender performance, insipid over the counter markets and a weak rand," JPMorgan said. – Bloomberg

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Related stories

SME airs dirty laundry on ‘fronting’

A small business is accusing a Bidvest-affiliated company of turning its partnership one-sided

KFC falls fowl in Britain with chicken run

Hundreds of KFC outlets remained shut in the the UK due to a supply crisis after the company changed delivery partners

Frenzy of misinformation at the Nasrec expo centre

Fake news about each factions — and their strategies to take down the competitions — abound at #ANC54

Bitcoin: a pocketful of cryptonite

Invest in the risky cryptocurrency only if you are prepared to lose everything

SA football agents to be prosecuted for price fixing

A statement released by the Competition Commission, SAFIA and its members "agreed to charge soccer players and coaches a standard 10% commission fee".

Failed takeover bid takes toll on Adcock

The healthcare company has posted a loss in the wake of a failed stock offer.
Advertising

Vaccine trial results due in December

If successful, it will then have to be manufactured and distributed

White men still rule and earn more

Women and black people occupy only a few seats at the JSE table, the latest PwC report has found

The PPE scandal that the Treasury hasn’t touched

Many government officials have been talking tough about dealing with rampant corruption in PPE procurement but the majority won't even release names of who has benefited from the R10-billion spend

ANC still at odds over how to tackle leaders facing...

The ANC’s top six has been mandated to work closely with its integrity committee to tackle claims of corruption against senior party members
Advertising

press releases

Loading latest Press Releases…

The best local and international journalism

handpicked and in your inbox every weekday